This company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsXylo Technologies（XYLO）株式概要技術系企業であるザイロ・テクノロジーズ・リミテッドは、米国、欧州、英国、イスラエル、カナダ、アジア、そして国際的に医療関連機器や製品を提供している。 詳細XYLO ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析意味のある時価総額がありません ( $6M )過去5年間で収益は年間14.6%減少しました。 過去1年間で株主の希薄化は大幅に進んだ すべてのリスクチェックを見るXYLO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$5.0798.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-16m198m2016201920222025202620282031Revenue US$197.8mEarnings US$25.1mAdvancedSet Fair ValueView all narrativesXylo Technologies Ltd 競合他社Ekso Bionics HoldingsSymbol: NasdaqCM:EKSOMarket cap: US$42.0mSTRATA Skin SciencesSymbol: OTCPK:SSKNMarket cap: US$712.5kNuwellisSymbol: NasdaqCM:NUWEMarket cap: US$420.7kINVO FertilitySymbol: NasdaqCM:IVFMarket cap: US$2.6m価格と性能株価の高値、安値、推移の概要Xylo Technologies過去の株価現在の株価US$5.0752週高値US$5.8552週安値US$2.71ベータ0.171ヶ月の変化-2.03%3ヶ月変化-3.80%1年変化40.44%3年間の変化-79.56%5年間の変化-91.44%IPOからの変化-99.93%最新ニュースお知らせ • Aug 23L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO).L.I.A. Pure Capital Ltd. proposed to acquire remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) for $3.5 million on March 4, 2025. The Amended Request increases Pure Capital’s proposal for the acquisition of the remaining 91.13% of the Company’s issued and outstanding share capital to an updated purchase price of $0.13125 per ordinary share of the Company (or $5.25 per American Depositary Share. The Amended Request further clarifies, subject to shareholder approval of the Arrangement, that (i) Pure Capital commits to purchase restricted share units granted to the Company’s employees, officers and directors that are subject to acceleration upon a change of control; and (ii) the Company will purchase customary run-off insurance as of the date the Arrangement becomes effective. The Court has given the Company until March 12, 2025, to submit a response to the Amended Request. The parties will finalize the Arrangement only if the parties satisfy or waive certain conditions including Israeli court approval. The board of directors of Xylo Technologies Ltd has decided not to object and has approved the proposal, considering it to be fair. As of May 27, 2025, Xylo Technologies Ltd shareholders approved the transaction in the general meeting. The transaction remains subject to approval by the Tel Aviv District Court. As of June 05, 2025, Viewbix Inc. has received approval for its shares of common stock to be listed on the Nasdaq Capital Market. As of June 22, 2025, the district court of Tel Aviv approved the arrangement between Xylo and its shareholders. L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) on August 22, 2025.New Risk • May 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 80% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Market cap is less than US$10m (US$6.66m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).Reported Earnings • May 02Full year 2024 earnings released: US$8.10 loss per share (vs US$25.34 loss in FY 2023)Full year 2024 results: US$8.10 loss per share (improved from US$25.34 loss in FY 2023). Revenue: US$29.9m (down 67% from FY 2023). Net loss: US$6.03m (loss narrowed 62% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (US$3.66m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Nancy Agmon-Levin was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Sep 26First half 2024 earnings released: US$11.33 loss per share (vs US$13.39 loss in 1H 2023)First half 2024 results: US$11.33 loss per share (improved from US$13.39 loss in 1H 2023). Revenue: US$19.3m (down 64% from 1H 2023). Net loss: US$8.17m (flat on 1H 2023). Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 27 percentage points per year, which is a significant difference in performance.最新情報をもっと見るRecent updatesお知らせ • Aug 23L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO).L.I.A. Pure Capital Ltd. proposed to acquire remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) for $3.5 million on March 4, 2025. The Amended Request increases Pure Capital’s proposal for the acquisition of the remaining 91.13% of the Company’s issued and outstanding share capital to an updated purchase price of $0.13125 per ordinary share of the Company (or $5.25 per American Depositary Share. The Amended Request further clarifies, subject to shareholder approval of the Arrangement, that (i) Pure Capital commits to purchase restricted share units granted to the Company’s employees, officers and directors that are subject to acceleration upon a change of control; and (ii) the Company will purchase customary run-off insurance as of the date the Arrangement becomes effective. The Court has given the Company until March 12, 2025, to submit a response to the Amended Request. The parties will finalize the Arrangement only if the parties satisfy or waive certain conditions including Israeli court approval. The board of directors of Xylo Technologies Ltd has decided not to object and has approved the proposal, considering it to be fair. As of May 27, 2025, Xylo Technologies Ltd shareholders approved the transaction in the general meeting. The transaction remains subject to approval by the Tel Aviv District Court. As of June 05, 2025, Viewbix Inc. has received approval for its shares of common stock to be listed on the Nasdaq Capital Market. As of June 22, 2025, the district court of Tel Aviv approved the arrangement between Xylo and its shareholders. L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) on August 22, 2025.New Risk • May 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 80% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Market cap is less than US$10m (US$6.66m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).Reported Earnings • May 02Full year 2024 earnings released: US$8.10 loss per share (vs US$25.34 loss in FY 2023)Full year 2024 results: US$8.10 loss per share (improved from US$25.34 loss in FY 2023). Revenue: US$29.9m (down 67% from FY 2023). Net loss: US$6.03m (loss narrowed 62% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (US$3.66m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Nancy Agmon-Levin was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Sep 26First half 2024 earnings released: US$11.33 loss per share (vs US$13.39 loss in 1H 2023)First half 2024 results: US$11.33 loss per share (improved from US$13.39 loss in 1H 2023). Revenue: US$19.3m (down 64% from 1H 2023). Net loss: US$8.17m (flat on 1H 2023). Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 27 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 23Full year 2023 earnings released: US$9.50 loss per share (vs US$6.04 loss in FY 2022)Full year 2023 results: US$9.50 loss per share (further deteriorated from US$6.04 loss in FY 2022). Revenue: US$91.7m (flat on FY 2022). Net loss: US$16.0m (loss widened 63% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 9 percentage points per year, which is a significant difference in performance.お知らせ • Apr 19Medigus Ltd.(NasdaqCM:MDGS) dropped from NASDAQ Composite IndexMediGus Ltd. has been removed from Nasdaq Composite Index.New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$4.74m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).お知らせ • Dec 26Medigus Ltd. Announces Launch of Unique Pilot of A Wireless Charging SolutionMedigus Ltd. announced the launch of a unique pilot of a wireless charging solution to meet the growing demand for electric vehicle (EV) charging in automated parking systems. This project was led by Charging Robotics Ltd., an innovator in wireless charging solutions and a subsidiary of Fuel Doctor Holdings Inc., a Delaware corporation listed on the OTC Market and owned by Medigus (67.15%). Charging Robotics specializes in developing cutting-edge wireless charging solutions designed to seamlessly integrate into the evolving landscape of electric vehicle (EV) infrastructure. Charging Robotics is at the forefront of innovation, focusing on the creation of wireless charging systems that can be deployed in various settings, including automated parking systems. In August 2023, the company announced that it started a pilot project with an automatic car park provider in Israel to evaluate Charging Robotics' wireless charging system for electric vehicles. For that purpose, in November 2023, the company secured funding from the Israel Innovation Authority to fund the pilot project. Between 2023 and 2032, this market is estimated to register a CAGR of 11.4%. Alongside the expected growth in the EV market, the combination of EVs and automated parking creates potential for a more sustainable and efficient future for transportation. The wireless charging system is set to answer the unmet need of charging EVs in automatic car parks. Automatic car parks are gaining popularity as they offer an ultra-efficient solution to park cars, while also reducing expensive real estate costs. However, since these are automated facilities, currently there is no way for the driver to connect a charging cable to the vehicle. This is a major concern and a market inhibit for automated parking manufacturers and EV manufacturers, particularly in areas where electric vehicles are growing rapidly- this is the con Charging Robotics aiming to address. Besides enabling EV charging in automatic car parks, the wireless charging system has numerous advantages, including: Seamless Integration: the wireless charging system will be seamlessly integrated into the automatic car park infrastructure, requiring minimal modifications to the existing layout. This ensures a minimum installation process while maximizing parking capacity. Convenient Charging Experience: drivers will start the system using a dedicated smart phone application, which will also notify the driver about the charging process. Scalability and Adaptability: the system's modular design enables easy scalability, allowing the parking lot operator to increase the number of chargers in the facility based on the number of electric vehicles. The system will be able to charge all electric vehicles at efficiencies of >93% which is outstanding for wireless charging systems.New Risk • Oct 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$7.58m market cap). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (5.8% increase in shares outstanding).New Risk • Jul 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$8.01m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding).お知らせ • Jul 01Medigus Ltd., Annual General Meeting, Aug 07, 2023Medigus Ltd., Annual General Meeting, Aug 07, 2023, at 10:00 US Eastern Standard Time. Location: Law Offices, 16 Abba Hillel Silver Rd. Ramat - Gan Israel Agenda: To consider approval of the re-election of Mr. Eli Cohen to serve as a director of the Company; to consider approval of a grant of restricted share units to the Company’s Chief Executive Officer, Chief Financial Officer and the Company’s directors; and Approval and ratification of the re-appointment of Brightman Almagor Zohar & Co., a member firm of Deloitte Touche Tohmatsu Limited, company's independent auditors for the year ending December 31, 2023, and its service until the next annual general meeting of shareholders to be held in 2024.お知らせ • Jun 08existing shareholders and office holders in ScoutCam acquired 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million.existing shareholders and office holders in ScoutCam acquired 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million on June 6, 2023. existing shareholders and office holders in ScoutCam completed the acquisition of 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million on June 6, 2023.Reported Earnings • May 06Full year 2022 earnings released: US$6.04 loss per share (vs US$4.42 profit in FY 2021)Full year 2022 results: US$6.04 loss per share (down from US$4.42 profit in FY 2021). Revenue: US$91.9m (up US$81.7m from FY 2021). Net loss: US$9.82m (down 244% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Price Target Changed • Nov 16Price target decreased to US$67.50Down from US$90.00, the current price target is provided by 1 analyst. New target price is 781% above last closing price of US$7.66. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$6.45 compared to earnings per share of US$4.42 last year.Seeking Alpha • Oct 19Medigus says ScoutCam appoints Yehu Ofer as CEOMedigus (NASDAQ:MDGS) has announced that ScoutCam (OTCQB:SCTC) appoints, Yehu Ofer as CEO, effective immediately. Mr. Ofer, 57, served as a colonel in the IAF, commanding two operational squadrons before commanding “Wing 15”, the optic and electronic intelligence wing of the IAF. He will lend his decades of experience to ScoutCam’s continued growth and success.Major Estimate Revision • Sep 30Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$12.4m to US$75.5m. EPS estimate fell from -US$0.02 to -US$0.43 per share. Medical Equipment industry in the US expected to see average net income growth of 9.6% next year. Consensus price target of US$4.50 unchanged from last update. Share price was steady at US$0.55 over the past week.Reported Earnings • Sep 24First half 2022 earnings released: US$0.15 loss per share (vs US$0.44 profit in 1H 2021)First half 2022 results: US$0.15 loss per share (down from US$0.44 profit in 1H 2021). Revenue: US$35.0m (up US$32.6m from 1H 2021). Net loss: US$3.59m (down 137% from profit in 1H 2021). Revenue is expected to decline by 49% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in the US are expected to grow by 7.8%. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.Seeking Alpha • Sep 23Medigus reports 1H resultsMedigus press release (NASDAQ:MDGS): 1H Net loss of $4.75M Revenue of $34.95M (+1362.3% Y/Y). Cash and cash equivalents as of June 30, 2022 were $22.1 million Shareholders’ equity improved to $53.19 million as of June 30, 2022, up from $51.43 million at December 31, 2021 Shares +16% PM.分析記事 • Sep 22What Does Medigus Ltd.'s (NASDAQ:MDGS) Share Price Indicate?Medigus Ltd. ( NASDAQ:MDGS ), might not be a large cap stock, but it received a lot of attention from a substantial...Seeking Alpha • Sep 08Medigus board files a motion to approve an up to $1.6M dividend distributionMedigus (NASDAQ:MDGS) said on Thursday it had filed a motion with the Tel Aviv District Court Economic Department for approval of a dividend distribution up to of $1.6M The Company’s motion, if approved as requested, would permit the Company to distribute a dividend to the holders of the Company’s American Depositary Shares in proportion to their respective holdings. Medigus is seeking a court approval for a dividend distribution in light of various legal restrictions that nullified its ability to buy back its shares under a previous court approval for a buyback, the company said.分析記事 • May 10Is Now An Opportune Moment To Examine Medigus Ltd. (NASDAQ:MDGS)?Medigus Ltd. ( NASDAQ:MDGS ), might not be a large cap stock, but it received a lot of attention from a substantial...Reported Earnings • May 01Full year 2021 earnings released: EPS: US$0.20 (vs US$0.65 loss in FY 2020)Full year 2021 results: EPS: US$0.20 (up from US$0.65 loss in FY 2020). Revenue: US$10.1m (up US$9.59m from FY 2020). Net income: US$6.79m (up US$11.1m from FY 2020). Profit margin: 67% (up from net loss in FY 2020). Over the next year, revenue is expected to shrink by 38% compared to a 9.8% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 25% share price gain to US$1.10, the stock trades at a trailing P/E ratio of 3.3x. Average forward P/E is 34x in the Medical Equipment industry in the US. Total loss to shareholders of 62% over the past three years.Valuation Update With 7 Day Price Move • Nov 23Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to US$1.22, the stock trades at a trailing P/E ratio of 3.6x. Average forward P/E is 35x in the Medical Equipment industry in the US. Total loss to shareholders of 64% over the past three years.Board Change • Oct 31High number of new directorsIndependent Chairman of the Board Eli Yoresh was the last director to join the board, commencing their role in 2020.分析記事 • Sep 28We Believe Medigus' (NASDAQ:MDGS) Earnings Are A Poor Guide For Its ProfitabilityWe didn't see Medigus Ltd.'s ( NASDAQ:MDGS ) stock surge when it reported robust earnings recently. We think that...Reported Earnings • Sep 26First half 2021 earnings released: EPS US$0.44 (vs US$0.56 loss in 1H 2020)First half 2021 results: Net income: US$9.79m (up US$12.3m from 1H 2020). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Feb 10New 90-day high: US$3.69The company is up 84% from its price of US$2.01 on 11 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.株主還元XYLOUS Medical EquipmentUS 市場7D-1.2%-0.5%0.9%1Y40.4%-20.1%24.5%株主還元を見る業界別リターン: XYLO過去 1 年間で-20.1 % の収益を上げたUS Medical Equipment業界を上回りました。リターン対市場: XYLO過去 1 年間で24.5 % の収益を上げたUS市場を上回りました。価格変動Is XYLO's price volatile compared to industry and market?XYLO volatilityXYLO Average Weekly Movement4.9%Medical Equipment Industry Average Movement8.8%Market Average Movement7.2%10% most volatile stocks in US Market16.7%10% least volatile stocks in US Market3.1%安定した株価: XYLO 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: XYLOの 週次ボラティリティ は、過去 1 年間で11%から5%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト199938Liron Carmelwww.medigus.comキシロ・テクノロジーズ・リミテッド（Xylo Technologies Ltd）は技術系企業で、米国、欧州、英国、イスラエル、カナダ、アジア、および国際的に医療関連機器および製品を提供している。法人部門、オンライン広告＆インターネットトラフィックルーティング部門、オンラインイベント管理部門、不動産・エレクトロニクス部門を通じて事業を展開している。同社は、胃食道逆流症の治療に使用される内視鏡システム「メディガス超音波外科用エンドステープラー」を提供している。また、デジタル広告プラットフォームの提供や、アマゾンのオンラインマーケットプレイスで様々な消費者向け商品を販売するオンラインストアの運営、オンラインイベント管理・チケット販売プラットフォームの運営も行っている。さらに、ワイヤレス車両バッテリー充電技術やモジュール式電子車両の開発も行っている。以前はMedigus Ltd.として知られていたが、2024年4月にXylo Technologies Ltd.に社名変更。ザイロ・テクノロジーズ社は1999年に法人化され、イスラエルのテルアビブに本社を置いている。もっと見るXylo Technologies Ltd 基礎のまとめXylo Technologies の収益と売上を時価総額と比較するとどうか。XYLO 基礎統計学時価総額US$6.49m収益（TTM）-US$6.03m売上高(TTM)US$29.86m0.2xP/Sレシオ-1.1xPER（株価収益率XYLO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計XYLO 損益計算書（TTM）収益US$29.86m売上原価US$23.18m売上総利益US$6.68mその他の費用US$12.71m収益-US$6.03m直近の収益報告Dec 31, 2024次回決算日該当なし一株当たり利益（EPS）-4.70グロス・マージン22.38%純利益率-20.19%有利子負債／自己資本比率39.0%XYLO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/23 04:15終値2025/08/21 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Xylo Technologies Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Rommel DionisioAegis Capital CorporationJeffrey CohenLadenburg Thalmann & CompanyChristopher LewisRoth Capital Partners
お知らせ • Aug 23L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO).L.I.A. Pure Capital Ltd. proposed to acquire remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) for $3.5 million on March 4, 2025. The Amended Request increases Pure Capital’s proposal for the acquisition of the remaining 91.13% of the Company’s issued and outstanding share capital to an updated purchase price of $0.13125 per ordinary share of the Company (or $5.25 per American Depositary Share. The Amended Request further clarifies, subject to shareholder approval of the Arrangement, that (i) Pure Capital commits to purchase restricted share units granted to the Company’s employees, officers and directors that are subject to acceleration upon a change of control; and (ii) the Company will purchase customary run-off insurance as of the date the Arrangement becomes effective. The Court has given the Company until March 12, 2025, to submit a response to the Amended Request. The parties will finalize the Arrangement only if the parties satisfy or waive certain conditions including Israeli court approval. The board of directors of Xylo Technologies Ltd has decided not to object and has approved the proposal, considering it to be fair. As of May 27, 2025, Xylo Technologies Ltd shareholders approved the transaction in the general meeting. The transaction remains subject to approval by the Tel Aviv District Court. As of June 05, 2025, Viewbix Inc. has received approval for its shares of common stock to be listed on the Nasdaq Capital Market. As of June 22, 2025, the district court of Tel Aviv approved the arrangement between Xylo and its shareholders. L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) on August 22, 2025.
New Risk • May 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 80% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Market cap is less than US$10m (US$6.66m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
Reported Earnings • May 02Full year 2024 earnings released: US$8.10 loss per share (vs US$25.34 loss in FY 2023)Full year 2024 results: US$8.10 loss per share (improved from US$25.34 loss in FY 2023). Revenue: US$29.9m (down 67% from FY 2023). Net loss: US$6.03m (loss narrowed 62% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (US$3.66m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Nancy Agmon-Levin was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Sep 26First half 2024 earnings released: US$11.33 loss per share (vs US$13.39 loss in 1H 2023)First half 2024 results: US$11.33 loss per share (improved from US$13.39 loss in 1H 2023). Revenue: US$19.3m (down 64% from 1H 2023). Net loss: US$8.17m (flat on 1H 2023). Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 27 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 23L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO).L.I.A. Pure Capital Ltd. proposed to acquire remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) for $3.5 million on March 4, 2025. The Amended Request increases Pure Capital’s proposal for the acquisition of the remaining 91.13% of the Company’s issued and outstanding share capital to an updated purchase price of $0.13125 per ordinary share of the Company (or $5.25 per American Depositary Share. The Amended Request further clarifies, subject to shareholder approval of the Arrangement, that (i) Pure Capital commits to purchase restricted share units granted to the Company’s employees, officers and directors that are subject to acceleration upon a change of control; and (ii) the Company will purchase customary run-off insurance as of the date the Arrangement becomes effective. The Court has given the Company until March 12, 2025, to submit a response to the Amended Request. The parties will finalize the Arrangement only if the parties satisfy or waive certain conditions including Israeli court approval. The board of directors of Xylo Technologies Ltd has decided not to object and has approved the proposal, considering it to be fair. As of May 27, 2025, Xylo Technologies Ltd shareholders approved the transaction in the general meeting. The transaction remains subject to approval by the Tel Aviv District Court. As of June 05, 2025, Viewbix Inc. has received approval for its shares of common stock to be listed on the Nasdaq Capital Market. As of June 22, 2025, the district court of Tel Aviv approved the arrangement between Xylo and its shareholders. L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) on August 22, 2025.
New Risk • May 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 80% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Market cap is less than US$10m (US$6.66m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
Reported Earnings • May 02Full year 2024 earnings released: US$8.10 loss per share (vs US$25.34 loss in FY 2023)Full year 2024 results: US$8.10 loss per share (improved from US$25.34 loss in FY 2023). Revenue: US$29.9m (down 67% from FY 2023). Net loss: US$6.03m (loss narrowed 62% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (US$3.66m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Nancy Agmon-Levin was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Sep 26First half 2024 earnings released: US$11.33 loss per share (vs US$13.39 loss in 1H 2023)First half 2024 results: US$11.33 loss per share (improved from US$13.39 loss in 1H 2023). Revenue: US$19.3m (down 64% from 1H 2023). Net loss: US$8.17m (flat on 1H 2023). Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 27 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 23Full year 2023 earnings released: US$9.50 loss per share (vs US$6.04 loss in FY 2022)Full year 2023 results: US$9.50 loss per share (further deteriorated from US$6.04 loss in FY 2022). Revenue: US$91.7m (flat on FY 2022). Net loss: US$16.0m (loss widened 63% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 9 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 19Medigus Ltd.(NasdaqCM:MDGS) dropped from NASDAQ Composite IndexMediGus Ltd. has been removed from Nasdaq Composite Index.
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$4.74m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).
お知らせ • Dec 26Medigus Ltd. Announces Launch of Unique Pilot of A Wireless Charging SolutionMedigus Ltd. announced the launch of a unique pilot of a wireless charging solution to meet the growing demand for electric vehicle (EV) charging in automated parking systems. This project was led by Charging Robotics Ltd., an innovator in wireless charging solutions and a subsidiary of Fuel Doctor Holdings Inc., a Delaware corporation listed on the OTC Market and owned by Medigus (67.15%). Charging Robotics specializes in developing cutting-edge wireless charging solutions designed to seamlessly integrate into the evolving landscape of electric vehicle (EV) infrastructure. Charging Robotics is at the forefront of innovation, focusing on the creation of wireless charging systems that can be deployed in various settings, including automated parking systems. In August 2023, the company announced that it started a pilot project with an automatic car park provider in Israel to evaluate Charging Robotics' wireless charging system for electric vehicles. For that purpose, in November 2023, the company secured funding from the Israel Innovation Authority to fund the pilot project. Between 2023 and 2032, this market is estimated to register a CAGR of 11.4%. Alongside the expected growth in the EV market, the combination of EVs and automated parking creates potential for a more sustainable and efficient future for transportation. The wireless charging system is set to answer the unmet need of charging EVs in automatic car parks. Automatic car parks are gaining popularity as they offer an ultra-efficient solution to park cars, while also reducing expensive real estate costs. However, since these are automated facilities, currently there is no way for the driver to connect a charging cable to the vehicle. This is a major concern and a market inhibit for automated parking manufacturers and EV manufacturers, particularly in areas where electric vehicles are growing rapidly- this is the con Charging Robotics aiming to address. Besides enabling EV charging in automatic car parks, the wireless charging system has numerous advantages, including: Seamless Integration: the wireless charging system will be seamlessly integrated into the automatic car park infrastructure, requiring minimal modifications to the existing layout. This ensures a minimum installation process while maximizing parking capacity. Convenient Charging Experience: drivers will start the system using a dedicated smart phone application, which will also notify the driver about the charging process. Scalability and Adaptability: the system's modular design enables easy scalability, allowing the parking lot operator to increase the number of chargers in the facility based on the number of electric vehicles. The system will be able to charge all electric vehicles at efficiencies of >93% which is outstanding for wireless charging systems.
New Risk • Oct 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$7.58m market cap). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (5.8% increase in shares outstanding).
New Risk • Jul 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$8.01m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding).
お知らせ • Jul 01Medigus Ltd., Annual General Meeting, Aug 07, 2023Medigus Ltd., Annual General Meeting, Aug 07, 2023, at 10:00 US Eastern Standard Time. Location: Law Offices, 16 Abba Hillel Silver Rd. Ramat - Gan Israel Agenda: To consider approval of the re-election of Mr. Eli Cohen to serve as a director of the Company; to consider approval of a grant of restricted share units to the Company’s Chief Executive Officer, Chief Financial Officer and the Company’s directors; and Approval and ratification of the re-appointment of Brightman Almagor Zohar & Co., a member firm of Deloitte Touche Tohmatsu Limited, company's independent auditors for the year ending December 31, 2023, and its service until the next annual general meeting of shareholders to be held in 2024.
お知らせ • Jun 08existing shareholders and office holders in ScoutCam acquired 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million.existing shareholders and office holders in ScoutCam acquired 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million on June 6, 2023. existing shareholders and office holders in ScoutCam completed the acquisition of 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million on June 6, 2023.
Reported Earnings • May 06Full year 2022 earnings released: US$6.04 loss per share (vs US$4.42 profit in FY 2021)Full year 2022 results: US$6.04 loss per share (down from US$4.42 profit in FY 2021). Revenue: US$91.9m (up US$81.7m from FY 2021). Net loss: US$9.82m (down 244% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Price Target Changed • Nov 16Price target decreased to US$67.50Down from US$90.00, the current price target is provided by 1 analyst. New target price is 781% above last closing price of US$7.66. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$6.45 compared to earnings per share of US$4.42 last year.
Seeking Alpha • Oct 19Medigus says ScoutCam appoints Yehu Ofer as CEOMedigus (NASDAQ:MDGS) has announced that ScoutCam (OTCQB:SCTC) appoints, Yehu Ofer as CEO, effective immediately. Mr. Ofer, 57, served as a colonel in the IAF, commanding two operational squadrons before commanding “Wing 15”, the optic and electronic intelligence wing of the IAF. He will lend his decades of experience to ScoutCam’s continued growth and success.
Major Estimate Revision • Sep 30Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$12.4m to US$75.5m. EPS estimate fell from -US$0.02 to -US$0.43 per share. Medical Equipment industry in the US expected to see average net income growth of 9.6% next year. Consensus price target of US$4.50 unchanged from last update. Share price was steady at US$0.55 over the past week.
Reported Earnings • Sep 24First half 2022 earnings released: US$0.15 loss per share (vs US$0.44 profit in 1H 2021)First half 2022 results: US$0.15 loss per share (down from US$0.44 profit in 1H 2021). Revenue: US$35.0m (up US$32.6m from 1H 2021). Net loss: US$3.59m (down 137% from profit in 1H 2021). Revenue is expected to decline by 49% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in the US are expected to grow by 7.8%. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
Seeking Alpha • Sep 23Medigus reports 1H resultsMedigus press release (NASDAQ:MDGS): 1H Net loss of $4.75M Revenue of $34.95M (+1362.3% Y/Y). Cash and cash equivalents as of June 30, 2022 were $22.1 million Shareholders’ equity improved to $53.19 million as of June 30, 2022, up from $51.43 million at December 31, 2021 Shares +16% PM.
分析記事 • Sep 22What Does Medigus Ltd.'s (NASDAQ:MDGS) Share Price Indicate?Medigus Ltd. ( NASDAQ:MDGS ), might not be a large cap stock, but it received a lot of attention from a substantial...
Seeking Alpha • Sep 08Medigus board files a motion to approve an up to $1.6M dividend distributionMedigus (NASDAQ:MDGS) said on Thursday it had filed a motion with the Tel Aviv District Court Economic Department for approval of a dividend distribution up to of $1.6M The Company’s motion, if approved as requested, would permit the Company to distribute a dividend to the holders of the Company’s American Depositary Shares in proportion to their respective holdings. Medigus is seeking a court approval for a dividend distribution in light of various legal restrictions that nullified its ability to buy back its shares under a previous court approval for a buyback, the company said.
分析記事 • May 10Is Now An Opportune Moment To Examine Medigus Ltd. (NASDAQ:MDGS)?Medigus Ltd. ( NASDAQ:MDGS ), might not be a large cap stock, but it received a lot of attention from a substantial...
Reported Earnings • May 01Full year 2021 earnings released: EPS: US$0.20 (vs US$0.65 loss in FY 2020)Full year 2021 results: EPS: US$0.20 (up from US$0.65 loss in FY 2020). Revenue: US$10.1m (up US$9.59m from FY 2020). Net income: US$6.79m (up US$11.1m from FY 2020). Profit margin: 67% (up from net loss in FY 2020). Over the next year, revenue is expected to shrink by 38% compared to a 9.8% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 25% share price gain to US$1.10, the stock trades at a trailing P/E ratio of 3.3x. Average forward P/E is 34x in the Medical Equipment industry in the US. Total loss to shareholders of 62% over the past three years.
Valuation Update With 7 Day Price Move • Nov 23Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to US$1.22, the stock trades at a trailing P/E ratio of 3.6x. Average forward P/E is 35x in the Medical Equipment industry in the US. Total loss to shareholders of 64% over the past three years.
Board Change • Oct 31High number of new directorsIndependent Chairman of the Board Eli Yoresh was the last director to join the board, commencing their role in 2020.
分析記事 • Sep 28We Believe Medigus' (NASDAQ:MDGS) Earnings Are A Poor Guide For Its ProfitabilityWe didn't see Medigus Ltd.'s ( NASDAQ:MDGS ) stock surge when it reported robust earnings recently. We think that...
Reported Earnings • Sep 26First half 2021 earnings released: EPS US$0.44 (vs US$0.56 loss in 1H 2020)First half 2021 results: Net income: US$9.79m (up US$12.3m from 1H 2020). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Feb 10New 90-day high: US$3.69The company is up 84% from its price of US$2.01 on 11 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.
